We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Alchemia Recruits First Patient to Pivotal Phase III Clinical Trial of HA-Irinotecan in Metastatic Colorectal Cancer


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Alchemia Recruits First Patient to Pivotal Phase III Clinical Trial of HA-Irinotecan in Metastatic Colorectal Cancer"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

HA-Irinotecan is a novel drug formulation that uses Alchemia's HyACT technology to target the widely used chemotherapy drug irinotecan directly to cancer cells. The 390-patient Phase III study will compare the safety and effectiveness of HA-Irinotecan with irinotecan in a double blind trial in second and third line metastatic colorectal cancer patients (mCRC) when administered as part of the FOLFIRI regimen, a combination chemotherapy regimen that includes folinic acid, fluorouracil, and irinotecan. The primary objective of this study is to demonstrate that HA-Irinotecan provides superior efficacy as indicated by an increased Progression-Free Survival (PFS) period.

This pivotal Phase III trial is being conducted at 55 sites in Australia, Eastern and Western Europe. Of these, 27 sites are actively recruiting and it is anticipated that the remainder will initiate recruitment in the first quarter of 2012. It will take around 12 months to recruit the required 390 patients. The primary endpoint will be reached when 350 patients have experienced disease progression, anticipated to be achieved in Q3 2013.

"Investigators are very enthusiastic to recruit to this study as previous clinical experience with HA-Irinotecan has demonstrated it to be a very effective drug in delaying the growth of tumors in patients with colorectal cancer who had failed other treatment regimens," said Principal Investigator, Associate Professor Peter Gibbs. "We are excited by the tumor-targeting abilities of HA-Irinotecan and we hope that it will be successful in providing a significant clinical benefit to cancer patients. Importantly this benefit is likely to be seen with no increase in treatment side effects and even the possibility of reduced toxicity."

HA-Irinotecan is a new formulation of irinotecan which targets the drug to the tumor and increases its uptake into cancer cells. This occurs through a well established receptor-based mechanism. A Phase II trial of HA-Irinotecan in metastatic colorectal cancer showed a statistically significant increase in PFS compared with irinotecan (5.2 months vs 2.4 months, p=0.017) with no increase in toxicity. After consultation with both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), both regulatory agencies indicated that the successful completion of this single pivotal Phase III trial may be sufficient for registration in both the US and Europe.

"This trial is highly significant for the development of the HyACT technology," said Professor Tracey Brown, Chief Scientific Officer of Alchemia Oncology. "Following a successful Phase II result, this will provide the final proof that Alchemia's proprietary drug delivery platform is able to improve the efficacy of currently used anti-cancer agents by converting them from a non-specific therapy into a more effective tumor-targeted treatment. We hope that this will provide a significant clinical benefit to cancer patients."

Advertisement